5HJS

Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.72 Å
  • R-Value Free: 0.238 
  • R-Value Work: 0.208 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Identification and in Vivo Evaluation of Liver X Receptor beta-Selective Agonists for the Potential Treatment of Alzheimer's Disease.

Stachel, S.J.Zerbinatti, C.Rudd, M.T.Cosden, M.Suon, S.Nanda, K.K.Wessner, K.DiMuzio, J.Maxwell, J.Wu, Z.Uslaner, J.M.Michener, M.S.Szczerba, P.Brnardic, E.Rada, V.Kim, Y.Meissner, R.Wuelfing, P.Yuan, Y.Ballard, J.Holahan, M.Klein, D.J.Lu, J.Fradera, X.Parthasarathy, G.Uebele, V.N.Chen, Z.Li, Y.Li, J.Cooke, A.J.Bennett, D.J.Bilodeau, M.T.Renger, J.

(2016) J.Med.Chem. 59: 3489-3498

  • DOI: 10.1021/acs.jmedchem.6b00176
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Herein, we describe the development of a functionally selective liver X receptor β (LXRβ) agonist series optimized for Emax selectivity, solubility, and physical properties to allow efficacy and safety studies in vivo. Compound 9 showed central pharm ...

    Herein, we describe the development of a functionally selective liver X receptor β (LXRβ) agonist series optimized for Emax selectivity, solubility, and physical properties to allow efficacy and safety studies in vivo. Compound 9 showed central pharmacodynamic effects in rodent models, evidenced by statistically significant increases in apolipoprotein E (apoE) and ATP-binding cassette transporter levels in the brain, along with a greatly improved peripheral lipid safety profile when compared to those of full dual agonists. These findings were replicated by subchronic dosing studies in non-human primates, where cerebrospinal fluid levels of apoE and amyloid-β peptides were increased concomitantly with an improved peripheral lipid profile relative to that of nonselective compounds. These results suggest that optimization of LXR agonists for Emax selectivity may have the potential to circumvent the adverse lipid-related effects of hepatic LXR activity.


    Organizational Affiliation

    WuXi AppTec Company, Ltd. , Shanghai 200131, P. R. China.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Oxysterols receptor LXR-alpha
A, B
283Homo sapiensMutation(s): 0 
Gene Names: NR1H3 (LXRA)
Find proteins for Q13133 (Homo sapiens)
Go to Gene View: NR1H3
Go to UniProtKB:  Q13133
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Nuclear receptor coactivator 1
C, D
25Homo sapiensMutation(s): 0 
Gene Names: NCOA1 (BHLHE74, SRC1)
EC: 2.3.1.48
Find proteins for Q15788 (Homo sapiens)
Go to Gene View: NCOA1
Go to UniProtKB:  Q15788
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
C, D
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
668
Query on 668

Download SDF File 
Download CCD File 
A, B
2-chloro-4-{1'-[(2R)-2-hydroxy-3-methyl-2-(trifluoromethyl)butanoyl]-4,4'-bipiperidin-1-yl}-N,N-dimethylbenzamide
C25 H35 Cl F3 N3 O3
POYRTHYMXFSQBJ-XMMPIXPASA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.72 Å
  • R-Value Free: 0.238 
  • R-Value Work: 0.208 
  • Space Group: P 4 21 2
Unit Cell:
Length (Å)Angle (°)
a = 125.007α = 90.00
b = 125.007β = 90.00
c = 92.339γ = 90.00
Software Package:
Software NamePurpose
BUSTER-TNTrefinement
HKL-2000data collection
HKL-2000data scaling
PDB_EXTRACTdata extraction
HKL-2000data reduction
REFMACphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2016-04-06
    Type: Initial release
  • Version 1.1: 2016-04-20
    Type: Database references
  • Version 1.2: 2016-04-27
    Type: Database references